Mechanism of Masked Hypertension - Intervention
Withdrawn before enrolling · Phase 3
Conditions studied: Masked Hypertension
In brief
To test the hypothesis that sympatholytic antihypertensive antihypertensive therapy (αβ-blocker - carvedilol) will reduce out-of-clinic ambulatory BP to a greater extent by blocking sympathetic activity than non-sympatholytic antihypertensive medication (dihydropyridine calcium channel blocker - amlodipine) in individuals with masked hypertension.
Key facts
- Study ID
- NCT04121299
- Run by
- University of Alabama at Birmingham
- People needed
- 0
- Starts
- 2021-07-01
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2021-11-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hypertension Research Clinic at UAB — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.